• December 2, 2024 – New Cases Added to MDL

    Published On: December 11, 2024|Categories: Ozempic|By |

    In November, 79 new cases were added to the Ozempic MDL (Multidistrict Litigation), bringing the total number of filings to over 200 in just the past two months. The MDL now includes more than 1,300 pending cases which reflect the growing number of individuals who are looking for legal action due to negative effects linked to Ozempic.

  • November 20, 2024 – New Master Complaint

    Published On: December 11, 2024|Categories: Ozempic|By |

    Last week, attorneys representing plaintiffs in the Ozempic lawsuits filed a revised master complaint in the MDL (Multidistrict Litigation). This updated document refines the allegations against the defendants that include Novo Nordisk, with a sharper focus on claims regarding the drug’s role. It causes gastrointestinal injuries and other serious side effects.

    What is a master complaint? In an MDL, a master complaint combines common allegations and claims from individual lawsuits into one unified document, providing a clear framework for the litigation. Plaintiffs then file short-form complaints that reference the master complaint, detailing their unique experiences and specific claims. This process streamlines the legal proceedings and ensures consistency across the cases.

  • November 12, 2024 – Minimizing Gastroparesis Risks

    Published On: December 11, 2024|Categories: Ozempic|By |

    As the number of cases in the Ozempic MDL continues to rise, new filings are focusing on the claim that Novo Nordisk purposely minimized the risks of gastroparesis in its marketing. Plaintiffs’ lawyers argue that the company was aware of Ozempic’s effects on stomach motility but chose not to update the warning labels, fearing it might stop patients from starting or continuing the treatment.

    The failure to address gastroparesis risks early in the drug’s release is expected to be a central issue in the litigation. As a result, many lawyers are now prioritizing cases specifically involving gastroparesis-related complications.

  • September 12, 2024: Pretrial Discovery

    Published On: December 11, 2024|Categories: Ozempic|By |

    The court has scheduled early discovery and motion practice focused on preemption and the adequacy of warning labels in the Ozempic lawsuits. However, the issue of marketing discovery has not been fully addressed, and plaintiffs are now seeking permission to include it at this early stage through a new motion.

    Plaintiffs argue that marketing discovery is essential to the case, as pharmaceutical companies may downplay or obscure risks in their marketing, which can undermine the effectiveness of warnings provided on product labels. This is particularly significant given the stakes in this litigation. There is ample precedent supporting the relevance of marketing materials in evaluating the adequacy of warnings and in challenging preemption defenses, as marketing directly influences consumer perception and usage.